Biotech and Medical Venture Deals Roundup
by Adam Rubenstein
OnBioVC
Advanced BioHealing (La Jolla, CA) a regenerative medicine, artificial skin tissue and wound healing company raised $25.5M in Series C funding.The deal was led by Safeguard Scientific and was accompanied by Channel Medical Partners, Red Abbey Venture Partners, Canaan Partners and Wheatley Partners.
Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.
Trius Therapeutics (San Diego, CA) a developer of antibacterial drugs for the treatment of a broad range of infections, raised $20M Series A financing,, The round was led by Sofinnova Ventures, InterWest Partners, Prism VentureWorks and Versant Ventures.
Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.
Phenomix (San Diego, CA) a drug discovery and development company focused on novel drugs to inhibit therapeutic targets in the protease and kinase families.The most advanced programs are for treatment of Type 2 diabetes and for treatment of hepatitis C. The deal was led by Nomura Phase4 Ventures and was joined by JP Morgan Partners, Delphi Ventures, Baker Brothers Life Sciences Capital, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.
Cytochroma (Canada) a drug company focused on Psoriasis and chronic kidney disease raised Cnd$21M in Series C financing. Investors include VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund.
CicuLite (Hackensack, NJ) a medical device company focused on the development of a proprietary circulatory assist technology for the management of chronic heart failure, closed a $20M Series B. Investors included Forbion Capital Partners, Oxford Biosciences Partners, Foundation Medical Partners, and SB Life Science Ventures.
Bridge Pharmaceuticals, Inc. (San Francisco, CA) an international contract research organization closed a Series B financing of $35M. The round was led by Granite Global Ventures.
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 10, 2007
- March 03, 2007
____________________
OnBioVC
Advanced BioHealing (La Jolla, CA) a regenerative medicine, artificial skin tissue and wound healing company raised $25.5M in Series C funding.The deal was led by Safeguard Scientific and was accompanied by Channel Medical Partners, Red Abbey Venture Partners, Canaan Partners and Wheatley Partners.
Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.
Trius Therapeutics (San Diego, CA) a developer of antibacterial drugs for the treatment of a broad range of infections, raised $20M Series A financing,, The round was led by Sofinnova Ventures, InterWest Partners, Prism VentureWorks and Versant Ventures.
Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.
Phenomix (San Diego, CA) a drug discovery and development company focused on novel drugs to inhibit therapeutic targets in the protease and kinase families.The most advanced programs are for treatment of Type 2 diabetes and for treatment of hepatitis C. The deal was led by Nomura Phase4 Ventures and was joined by JP Morgan Partners, Delphi Ventures, Baker Brothers Life Sciences Capital, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.
Cytochroma (Canada) a drug company focused on Psoriasis and chronic kidney disease raised Cnd$21M in Series C financing. Investors include VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund.
CicuLite (Hackensack, NJ) a medical device company focused on the development of a proprietary circulatory assist technology for the management of chronic heart failure, closed a $20M Series B. Investors included Forbion Capital Partners, Oxford Biosciences Partners, Foundation Medical Partners, and SB Life Science Ventures.
Bridge Pharmaceuticals, Inc. (San Francisco, CA) an international contract research organization closed a Series B financing of $35M. The round was led by Granite Global Ventures.
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 10, 2007
- March 03, 2007
____________________
posted by Nico at
3:42 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home